FDA Holds Off Approval Of AstraZeneca Diabetes Treatment
By Sindhu Sundar ( October 16, 2015, 10:09 PM EDT) -- AstraZeneca said Friday that the U.S. Food and Drug Administration has held off on approving its Type 2 diabetes treatment for adults with the combination of the drugs saxagliptin and dapagliflozin and asked the London-based drugmaker for more clinical data on the treatment....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.